amyfaithho’s Activity

Sat May 10

NL

Article

amyfaithho published an article 10:00 AM

Will New Regulations on E-Cigs Hurt Big Tobacco?

New regulatory proposals on tobacco questionable on both passage and impact

Thu Apr 24

NL

Article

amyfaithho published an article 6:30 PM

Sarepta's Still a Gamble, Even With FDA Reversal

Will Sarepta finally get approval for eteplirsen?

Tue Apr 15

NL

Article

amyfaithho published an article 9:30 AM

Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences Inc. for Hep C Combo?

Merck plays catch-up while Bristol-Myers looks global.

Fri Apr 4

NL

Article

amyfaithho published an article 6:30 PM

What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?

Two drugs are hot on Pfizer’s tail.

Thu Apr 3

NL

Article

amyfaithho published an article 2:30 PM

Does Amgen Have the Next Lipitor on Its Hands?

Amgen leads the PCSK9-blocker class of cholesterol drugs.

Mon Mar 31

NL

Article

amyfaithho published an article 3:10 PM

FDA Review Incoming: Will Mannkind Finally Succeed?

Could a third rejection may be looming for MNKD inhalable insulin?

Tue Mar 18

NL

Article

amyfaithho published an article 6:30 PM

Trouble Ahead for Gilead and Sovaldi?

Idenix files suit atop $9 billion sales estimates for Gilead's Sovaldi

Tue Mar 11

NL

Article

amyfaithho published an article 9:30 AM

How Will This Latest Setback Affect Eli Lilly?

Concerns over Boerhringer Ingelheim plant delay approval of key diabetes agent

Tue Mar 4

NL

Article

amyfaithho published an article 9:30 AM

Why Would Roche Return to the Antibiotics Market?

Roche’s new deal with Discuva marks major private sector commitment to antibiotic development

Mon Mar 3

NL

Article

amyfaithho published an article 2:30 PM

Bristol-Myers Closing in on Gilead in Hepatitis C Race

New breakthrough designation could help Bristol-Myers compete more quickly with market-leader Gilead.

Fri Feb 28

NL

Article

amyfaithho published an article 4:36 PM

Is This Drug Enough To Revive Hope in Eli Lilly's Pipeline?

Eli Lilly struggles to gain approval and regain diabetes market share.

Tue Feb 11

NL

Article

amyfaithho published an article 6:34 PM

Gilead Combination Hepatitis C Filing Solidifies Its Leadership

AbbVie and Bristol-Myers unlikely to catch Gilead in race for oral hep C combination therapy

NL

Article

amyfaithho published an article 6:30 PM

AstraZeneca Struggles to Meet Expectations

CEO Pascal Soriot is fighting an uphill battling winning investors on pipeline.

NL

Article

amyfaithho published an article 6:08 PM

Antidepressant R&D takes another hit with J&J

Multiple approaches to depression treatment fail trials

Tue Feb 4

NL

Article

amyfaithho published an article 5:15 PM

Companies Limp Towards a Duchenne Treatment – Is There Hope of a Finish Line?

2014 starts a dismal year for Duchenne prospects by Sarepta, Prosensa, PTC and Retrophin

Mon Feb 3

NL

Article

amyfaithho published an article 4:19 PM

AbbVie's Challenge to Gilead in Hepatitis C Therapies

New clinical data from AbbVie spice up hepatitis C market and prospects for the company

Sun Feb 2

NL

Article

amyfaithho published an article 12:21 PM

Could Ariad Be Set for a Comeback?

Ariad's troubled drug Iclusig undergoes an official return to market.

NL

Article

amyfaithho published an article 10:00 AM

Fierce Competition in the Diabetes Drug Market

GSK, Eli Lilly and Sanofi fight for already-crowded diabetes market share

Fri Jan 24

NL

Article

amyfaithho published an article 1:10 PM

UK Eyes Success of US FDA Breakthrough Designation Program

Expedited review of drugs in UK would be a win for patients, even bigger win for investors

Wed Jan 22

NL

Article

amyfaithho published an article 10:30 AM

Bristol-Myers Squibb Hepatitis C Therapy Opens Up Combination Options

Bristol-Myers Squibb breaks from seeking a combination with Gilead on hepatitis C treatment.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating < 20
Player Rank 0 out of 75035
Score 0.00
Score Change Today 0
Accuracy 0.00%
Active Picks 3
Total Picks 3
Best Pick GILD (+49.59)
Worst Pick RAD (-29.68)
Average Score per Pick 0.00
Charms Earned 0
Highest Rated Favorite No Favorites Selected
Go to amyfaithho’s CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show amyfaithho’s 10 Latest Posts